KOL Views: Emicizumab hits its marks in first Phase III – homerun for Roche and what does it mean for Shire, Novo Nordisk?

Results from the first Phase III trial of Roche’s emicizumab (formerly known as ACE910) appear to substantiate the paradigm-shifting expectations currently assigned to the bispecific mAb as a treatment for haemophilia A, which will inevitably have major ramifications for the established commercial players in the space.

To provide FirstWord readers with a better understanding of what the results mean for emicizumab and competing products, we are hosting an expert call with a key opinion leader this week.

Key topics that will be discussed during the call include, among other things… how quickly and in what patient groups will emicizumab become the new standard of care, what impact will this have on products like Shire’s Feiba and Novo Nordisk’s NovoSeven, how concerning are the thromboembolic events and in what way might they impact emicizumab’s use and penetration, does confirmation that events occurred exclusively in patients already treated with Feiba represent a headwind for Shire, as well as expectations for the Roche agent in non-inhibitor patients?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving haemophilia A treatment landscape.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.